Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $281.6 million.

  • ImmunityBio's Cash from Financing Activities rose 1013.59% to $173.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $452.3 million, marking a year-over-year increase of 20.53%. This contributed to the annual value of $281.6 million for FY2024, which is 49.56% down from last year.
  • As of FY2024, ImmunityBio's Cash from Financing Activities stood at $281.6 million, which was down 49.56% from $558.3 million recorded in FY2023.
  • ImmunityBio's Cash from Financing Activities' 5-year high stood at $558.3 million during FY2023, with a 5-year trough of $150.7 million in FY2020.
  • Moreover, its 3-year median value for Cash from Financing Activities was $281.6 million (2024), whereas its average is $357.9 million.
  • In the last 5 years, ImmunityBio's Cash from Financing Activities surged by 235.45% in 2021 and then crashed by 53.78% in 2022.
  • ImmunityBio's Cash from Financing Activities (Yearly) stood at $150.7 million in 2020, then soared by 235.45% to $505.4 million in 2021, then plummeted by 53.78% to $233.6 million in 2022, then surged by 139.00% to $558.3 million in 2023, then slumped by 49.56% to $281.6 million in 2024.